New Neuroendocrine Cancer Study Findings Have Been Reported by Investigators at Postgraduate Institute of Medical Education and Research (Sunitinib In Tandem With <superscript>177</superscript>lu-dotatate Therapy In Advanced Pancreatic Neuroendocrine Tumor a.
In: Gastroenterology Week, 2024-02-13, S. 1331-1331
serialPeriodical
Zugriff:
A recent study conducted at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, explored the use of combined treatments for advanced pancreatic neuroendocrine tumors (NETs). The researchers found that the use of sunitinib, a multikinase inhibitor, in tandem with 177Lu-dotatate therapy, a peptide radioreceptor therapy, resulted in a reinforced response to treatment in a 40-year-old patient. This study highlights the potential benefits of combining different systemic treatment modalities for pancreatic NETs. Further research in this area is needed to better understand the effectiveness of these combined treatments. [Extracted from the article]
Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Neuroendocrine Cancer Study Findings Have Been Reported by Investigators at Postgraduate Institute of Medical Education and Research (Sunitinib In Tandem With <superscript>177</superscript>lu-dotatate Therapy In Advanced Pancreatic Neuroendocrine Tumor a.
|
---|---|
Zeitschrift: | Gastroenterology Week, 2024-02-13, S. 1331-1331 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6756 (print) |
Schlagwort: |
|
Sonstiges: |
|